GlassScriptPhysician profile
Sara Mauk
NPI 1235756461
$3,215.95
in general payments reported to CMS, 2019-2025
23 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $35.57 · 2023: $472 · 2024: $1,299 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.21 |
| Education | $271.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $543.96 | 2023-2025 | Dupixent |
| Genzyme Corporation | $492.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $407.09 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Baxter Healthcare | $374.88 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $257.13 | 2021-2025 | Arikayce, Brinsupri |
| Averitas Pharma INC. | $198.91 | 2023-2025 | Qutenza |
| Sanofi-Aventis U.S. LLC | $173.94 | 2024-2025 | |
| Glaxosmithkline, LLC. | $143.86 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Merck Sharp & Dohme LLC | $112.60 | 2023-2024 | Zerbaxa, Recarbrio, Dificid |
| Mallinckrodt Hospital Products INC. | $68.73 | 2021-2025 | Acthar |
| Viatris Specialty LLC | $55.04 | 2025 | Yupelri |
| Amgen INC. | $53.19 | 2023 | Tezspire |
| United Therapeutics Corporation | $53.01 | 2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $52.53 | 2023-2024 | Opsumit |
| Tersera Therapeutics LLC | $42.05 | 2023-2024 | Prialt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $33.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $26.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.48 | 2025 | Ofev |
| Mylan Specialty L.P. | $23.75 | 2024 | Yupelri |
| Grt US Holding, INC. | $20.38 | 2022 | |
| Inogen, INC. | $19.96 | 2023 | Inogen |
| Ani Pharmaceuticals, INC. | $19.93 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $17.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Mauk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.